$MACK Headlines Merrimack Pharma shares surge
Post# of 74551
Posted On: 09/30/2014 11:49:58 AM
$MACK Headlines
Merrimack Pharma shares surge on licensing pact with Baxter 7:54 a.m. Sept. 24, 2014 - Tomi Kilgore
Stock futures rise on Bernanke rate comments 5:46 p.m. July 10, 2013 - Wallace Witkowski
Merrimack to offer $50 mln in stock, $75 mln notes 5:24 p.m. July 10, 2013 - MarketWatch.com
Stocks to watch Friday: Goldman, Bally, Scotts 6:54 a.m. Aug. 10, 2012 - MarketWatch
IPO scorecard: Update on selected offering 2:18 p.m. June 8, 2012 - Dow Jones
Shares of Merrimack Pharmaceuticals off post IPO 3:19 a.m. March 30, 2012 - MarketWatch.com
Merrimack Pharmaceuticals (MACK) Strong On High Relative Volume Today 10:01 a.m. Today - TheStreet.com
How Merrimack Pharmaceuticals (MACK) Stock Stands Out in a Strong Industry - Tale of the Tape 8:36 a.m. Sept. 29, 2014 - Zacks.com
Will Merrimack (MACK) Continue to Surge Higher? - Tale of the Tape 10:09 a.m. Sept. 26, 2014 - Zacks.com
Merrimack Pharmaceuticals (MACK) Soars: Stock Adds 7.4% is Session - Tale of the Tape 9:39 a.m. Sept. 26, 2014 - Zacks.com
Baxter and Merrimack Collaborate on Drug Development - Analyst Blog 1:10 p.m. Sept. 25, 2014 - Zacks.com
Update: Merrimack Licenses MM-398 - Value Potential Dramatically Improves 11:30 a.m. Sept. 24, 2014 - Seeking Alpha
Why Merrimack Pharmaceuticals (MACK) Stock Hit a One-Year High Today 10:30 a.m. Sept. 24, 2014 - TheStreet.com
Merrimack Does Well to License Marginal Cancer Drug to Baxter 8:14 a.m. Sept. 24, 2014 - TheStreet.com
Merrimack Pharmaceuticals (MACK): Heavy Pre-Market Activity 8:10 a.m. Sept. 24, 2014 - TheStreet.com
Baxter, Merrimack to Collaborate on Pancreatic Cancer Drug 7:43 a.m. Sept. 24, 2014 - The Wall Street Journal Interactive Edition
Baxter and Merrimack collaborate on cancer drug 7:34 a.m. Sept. 24, 2014 - Seeking Alpha
Market Has Not Yet Noticed Potential in Merrimack Pharmaceuticals (MACK); Have You? - Tale of the Tape 8:39 a.m. Sept. 10, 2014 - Zacks.com
Can Merrimack Pharmaceuticals (MACK) Run Higher on Strong Earnings Estimate Revisions? - Tale of the Tape 8:43 a.m. Sept. 9, 2014 - Zacks.com
Will Merrimack Pharmaceuticals (MACK) Crush Estimates at Its Next Earnings Report? - Tale of the Tape 8:54 a.m. Aug. 20, 2014 - Zacks.com
10-Q: MERRIMACK PHARMACEUTICALS INC 4:05 p.m. Aug. 11, 2014 - Edgar Online - (EDG = 10Q, 10K)
Merrimack Pharmaceuticals' (MACK) CEO Bob Mulroy on Q2 2014 Results - Earnings Call Transcript 3:01 p.m. Aug. 11, 2014 - Seeking Alpha
Update: Merrimack Earnings - Looming Concerns Still Remain 2:04 p.m. Aug. 11, 2014 - Seeking Alpha
More on Merrimack Pharma Q2 results 8:02 a.m. Aug. 11, 2014 - Seeking Alpha
Is Now The Time To Buy Merrimack Pharmaceuticals? 11:17 a.m. July 8, 2014 - Seeking Alpha
They're the Millers: Two Best Funds in Winners' Circle Contest 4:47 p.m. July 6, 2014 - The Wall Street Journal Interactive Edition
Merrimack Pharmaceuticals Presents Additional Phase 2 Biomarker Data Further Strengthening the Finding That MM-121 Increases Progression Free Survival in Patients With Biomarker Positive Metastatic Breast Cancer 8:00 a.m. Today - GlobeNewswire
PharmaEngine and Merrimack Amend MM-398 License Agreement 4:58 a.m. Sept. 26, 2014 - BusinessWire - BZX
Baxter and Merrimack Pharmaceuticals Enter into Exclusive Ex-U.S. Licensing Agreement to Develop and Commercialize Novel Cancer Compound MM-398 7:00 a.m. Sept. 24, 2014 - BusinessWire - BZX
Merrimack Pharmaceuticals to Present Clinical and Biomarker Data on Novel Antibody Therapeutics at the ESMO 2014 Congress 8:00 a.m. Sept. 19, 2014 - GlobeNewswire
Merrimack Pharmaceuticals Announces Initiation of HERMIONE, a Randomized Trial of MM-302 in Patients With Advanced HER2-Positive Breast Cancer to Support Application for Accelerated Approval 7:06 a.m. Aug. 11, 2014 - GlobeNewswire
Merrimack Pharmaceuticals Reports Second Quarter 2014 Financial Results 7:01 a.m. Aug. 11, 2014 - GlobeNewswire
Biotech Equities Technical Analysis -- BioMarin Pharma, Merrimack Pharma, Sangamo BioSciences, ZIOPHARM Oncology, and Dyax 8:50 a.m. Aug. 7, 2014 - PR Newswire - PRF
Merrimack Pharmaceuticals Announces Timing of Second Quarter 2014 Investor Conference Call 4:02 p.m. Aug. 4, 2014 - GlobeNewswire
Divestitures, Agreement for Developmental Rights, Data Presentations, Technical Update, and Licensing Agreements - Analyst Notes on Akorn, Merrimack, Avanir, Omeros and TG Therapeutics 6:40 a.m. June 27, 2014 - PR Newswire - PRF
Merrimack Pharmaceuticals Presents Data From Phase 3 NAPOLI-1 Study at the ESMO 16th World Congress on Gastrointestinal Cancer 4:05 p.m. June 25, 2014 - GlobeNewswire
Biotech R&D and Clinical Trials Lead To Potential Revenue Growth - Company's Data of Phase l & Phase ll For HCC Patients Highly Suggestive of Positive Clinical Activity 8:15 a.m. June 25, 2014 - PR Newswire - PRF
Merrimack Pharmaceuticals to Regain Worldwide Rights to Develop and Commercialize MM-121 4:15 p.m. June 19, 2014 - GlobeNewswire
Merrimack Pharmaceuticals Announces Oral Presentation of Additional Data Results in Phase 3 NAPOLI-1 Study at the ESMO 16th World Congress on Gastrointestinal Cancer 8:01 a.m. June 17, 2014 - GlobeNewswire
Battle of the Biotech Bands - A Great Time for a Great Cause 2:45 p.m. June 12, 2014 - PR Newswire - PRF
Merrimack Pharmaceuticals Presents Phase 1 Clinical Data Supporting Four Novel Antibody Therapeutic Programs at the 2014 ASCO Annual Meeting 4:00 p.m. June 2, 2014 - GlobeNewswire
Merrimack Pharmaceuticals Identifies Heregulin as Patient Response Biomarker for MM-121 and Standard of Care Therapy Across Multiple Cancers 9:36 a.m. June 2, 2014 - GlobeNewswire
Fundraising Support, Upcoming Conferences, Clinical Data Presentations, and Cash Dividends - Analyst Notes on WellCare, NPS Pharma, Merrimack Pharmaceuticals, CONMED and Haemonetics 8:00 a.m. May 28, 2014 - PR Newswire - PRF
Equities Marking a New High -- Research on JD.com, NRG Energy, Merrimack Pharma and Arris Group 5:40 a.m. May 28, 2014 - PR Newswire - PRF
Merrimack Pharmaceuticals to Present at the Jefferies 2014 Global Healthcare Conference 8:01 a.m. May 27, 2014 - GlobeNewswire
Merrimack Pharmaceuticals to Present Clinical Data Across Oncology Pipeline at ASCO 2014 5:25 p.m. May 22, 2014 - GlobeNewswire
Merrimack Pharma shares surge on licensing pact with Baxter 7:54 a.m. Sept. 24, 2014 - Tomi Kilgore
Stock futures rise on Bernanke rate comments 5:46 p.m. July 10, 2013 - Wallace Witkowski
Merrimack to offer $50 mln in stock, $75 mln notes 5:24 p.m. July 10, 2013 - MarketWatch.com
Stocks to watch Friday: Goldman, Bally, Scotts 6:54 a.m. Aug. 10, 2012 - MarketWatch
IPO scorecard: Update on selected offering 2:18 p.m. June 8, 2012 - Dow Jones
Shares of Merrimack Pharmaceuticals off post IPO 3:19 a.m. March 30, 2012 - MarketWatch.com
Merrimack Pharmaceuticals (MACK) Strong On High Relative Volume Today 10:01 a.m. Today - TheStreet.com
How Merrimack Pharmaceuticals (MACK) Stock Stands Out in a Strong Industry - Tale of the Tape 8:36 a.m. Sept. 29, 2014 - Zacks.com
Will Merrimack (MACK) Continue to Surge Higher? - Tale of the Tape 10:09 a.m. Sept. 26, 2014 - Zacks.com
Merrimack Pharmaceuticals (MACK) Soars: Stock Adds 7.4% is Session - Tale of the Tape 9:39 a.m. Sept. 26, 2014 - Zacks.com
Baxter and Merrimack Collaborate on Drug Development - Analyst Blog 1:10 p.m. Sept. 25, 2014 - Zacks.com
Update: Merrimack Licenses MM-398 - Value Potential Dramatically Improves 11:30 a.m. Sept. 24, 2014 - Seeking Alpha
Why Merrimack Pharmaceuticals (MACK) Stock Hit a One-Year High Today 10:30 a.m. Sept. 24, 2014 - TheStreet.com
Merrimack Does Well to License Marginal Cancer Drug to Baxter 8:14 a.m. Sept. 24, 2014 - TheStreet.com
Merrimack Pharmaceuticals (MACK): Heavy Pre-Market Activity 8:10 a.m. Sept. 24, 2014 - TheStreet.com
Baxter, Merrimack to Collaborate on Pancreatic Cancer Drug 7:43 a.m. Sept. 24, 2014 - The Wall Street Journal Interactive Edition
Baxter and Merrimack collaborate on cancer drug 7:34 a.m. Sept. 24, 2014 - Seeking Alpha
Market Has Not Yet Noticed Potential in Merrimack Pharmaceuticals (MACK); Have You? - Tale of the Tape 8:39 a.m. Sept. 10, 2014 - Zacks.com
Can Merrimack Pharmaceuticals (MACK) Run Higher on Strong Earnings Estimate Revisions? - Tale of the Tape 8:43 a.m. Sept. 9, 2014 - Zacks.com
Will Merrimack Pharmaceuticals (MACK) Crush Estimates at Its Next Earnings Report? - Tale of the Tape 8:54 a.m. Aug. 20, 2014 - Zacks.com
10-Q: MERRIMACK PHARMACEUTICALS INC 4:05 p.m. Aug. 11, 2014 - Edgar Online - (EDG = 10Q, 10K)
Merrimack Pharmaceuticals' (MACK) CEO Bob Mulroy on Q2 2014 Results - Earnings Call Transcript 3:01 p.m. Aug. 11, 2014 - Seeking Alpha
Update: Merrimack Earnings - Looming Concerns Still Remain 2:04 p.m. Aug. 11, 2014 - Seeking Alpha
More on Merrimack Pharma Q2 results 8:02 a.m. Aug. 11, 2014 - Seeking Alpha
Is Now The Time To Buy Merrimack Pharmaceuticals? 11:17 a.m. July 8, 2014 - Seeking Alpha
They're the Millers: Two Best Funds in Winners' Circle Contest 4:47 p.m. July 6, 2014 - The Wall Street Journal Interactive Edition
Merrimack Pharmaceuticals Presents Additional Phase 2 Biomarker Data Further Strengthening the Finding That MM-121 Increases Progression Free Survival in Patients With Biomarker Positive Metastatic Breast Cancer 8:00 a.m. Today - GlobeNewswire
PharmaEngine and Merrimack Amend MM-398 License Agreement 4:58 a.m. Sept. 26, 2014 - BusinessWire - BZX
Baxter and Merrimack Pharmaceuticals Enter into Exclusive Ex-U.S. Licensing Agreement to Develop and Commercialize Novel Cancer Compound MM-398 7:00 a.m. Sept. 24, 2014 - BusinessWire - BZX
Merrimack Pharmaceuticals to Present Clinical and Biomarker Data on Novel Antibody Therapeutics at the ESMO 2014 Congress 8:00 a.m. Sept. 19, 2014 - GlobeNewswire
Merrimack Pharmaceuticals Announces Initiation of HERMIONE, a Randomized Trial of MM-302 in Patients With Advanced HER2-Positive Breast Cancer to Support Application for Accelerated Approval 7:06 a.m. Aug. 11, 2014 - GlobeNewswire
Merrimack Pharmaceuticals Reports Second Quarter 2014 Financial Results 7:01 a.m. Aug. 11, 2014 - GlobeNewswire
Biotech Equities Technical Analysis -- BioMarin Pharma, Merrimack Pharma, Sangamo BioSciences, ZIOPHARM Oncology, and Dyax 8:50 a.m. Aug. 7, 2014 - PR Newswire - PRF
Merrimack Pharmaceuticals Announces Timing of Second Quarter 2014 Investor Conference Call 4:02 p.m. Aug. 4, 2014 - GlobeNewswire
Divestitures, Agreement for Developmental Rights, Data Presentations, Technical Update, and Licensing Agreements - Analyst Notes on Akorn, Merrimack, Avanir, Omeros and TG Therapeutics 6:40 a.m. June 27, 2014 - PR Newswire - PRF
Merrimack Pharmaceuticals Presents Data From Phase 3 NAPOLI-1 Study at the ESMO 16th World Congress on Gastrointestinal Cancer 4:05 p.m. June 25, 2014 - GlobeNewswire
Biotech R&D and Clinical Trials Lead To Potential Revenue Growth - Company's Data of Phase l & Phase ll For HCC Patients Highly Suggestive of Positive Clinical Activity 8:15 a.m. June 25, 2014 - PR Newswire - PRF
Merrimack Pharmaceuticals to Regain Worldwide Rights to Develop and Commercialize MM-121 4:15 p.m. June 19, 2014 - GlobeNewswire
Merrimack Pharmaceuticals Announces Oral Presentation of Additional Data Results in Phase 3 NAPOLI-1 Study at the ESMO 16th World Congress on Gastrointestinal Cancer 8:01 a.m. June 17, 2014 - GlobeNewswire
Battle of the Biotech Bands - A Great Time for a Great Cause 2:45 p.m. June 12, 2014 - PR Newswire - PRF
Merrimack Pharmaceuticals Presents Phase 1 Clinical Data Supporting Four Novel Antibody Therapeutic Programs at the 2014 ASCO Annual Meeting 4:00 p.m. June 2, 2014 - GlobeNewswire
Merrimack Pharmaceuticals Identifies Heregulin as Patient Response Biomarker for MM-121 and Standard of Care Therapy Across Multiple Cancers 9:36 a.m. June 2, 2014 - GlobeNewswire
Fundraising Support, Upcoming Conferences, Clinical Data Presentations, and Cash Dividends - Analyst Notes on WellCare, NPS Pharma, Merrimack Pharmaceuticals, CONMED and Haemonetics 8:00 a.m. May 28, 2014 - PR Newswire - PRF
Equities Marking a New High -- Research on JD.com, NRG Energy, Merrimack Pharma and Arris Group 5:40 a.m. May 28, 2014 - PR Newswire - PRF
Merrimack Pharmaceuticals to Present at the Jefferies 2014 Global Healthcare Conference 8:01 a.m. May 27, 2014 - GlobeNewswire
Merrimack Pharmaceuticals to Present Clinical Data Across Oncology Pipeline at ASCO 2014 5:25 p.m. May 22, 2014 - GlobeNewswire
(0)
(0)